• Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Patients with prediabetes and nonalcoholic steatohepatitis (NASH) benefit nearly as much from pioglitazone therapy as those with type-2 diabetes, researchers report in the April issue of Clinical Gastroenterology and Hepatology. The diabetes drug reduced fibrosis in non-diabetic patients with NASH, the clinical study found, although to a lesser extent than in patients

Read more

A New Drug for Diabetes and Fatty Liver Disease?

Obeticholic acid (OCA)—an agonist of the farnesoid X receptor (FXR)— increases insulin sensitivity and reduces markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), according to a study published in the September issue of Gastroenterology. Type 2 diabetes mellitus and

Read more